These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). HIV Netherlands Australia Thailand Research Collaboration. Kroon ED; Ungsedhapand C; Ruxrungtham K; Chuenyam M; Ubolyam S; Newell ME; van Leeuwen R; Kunanusont C; Buranapraditkul S; Sirivichayakul S; Lange JM; Cooper DA; Phanuphak P AIDS; 2000 Jul; 14(10):1349-56. PubMed ID: 10930149 [TBL] [Abstract][Full Text] [Related]
8. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. Martínez E; Larrousse M; Podzamczer D; Pérez I; Gutiérrez F; Loncá M; Barragán P; Deulofeu R; Casamitjana R; Mallolas J; Pich J; Gatell JM; AIDS; 2010 Jan; 24(3):F1-9. PubMed ID: 20009917 [TBL] [Abstract][Full Text] [Related]
9. Genital shedding of HIV after scheduled treatment interruption. Ananworanich J; Kerr SJ; Vernazza P; Mangclaviraj S; Chaithongwongwatthana S; Chotnopparatpattara P; Mahanontharit A; Ubolyam S; Jupimai T; Cooper DA; Ruxrungtham K; Hirschel B; Int J STD AIDS; 2011 Feb; 22(2):61-6. PubMed ID: 21427425 [TBL] [Abstract][Full Text] [Related]
10. [Markers of endothelial injury and plasma adipocytokine in antiretroviral-naive HIV patients]. Li L; Chen J; Sun FY; Liu L; Zhang RF; Zheng YF; Lu HZ Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):136-9. PubMed ID: 21418835 [TBL] [Abstract][Full Text] [Related]
11. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients. AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538 [TBL] [Abstract][Full Text] [Related]
12. Dendritic cell immunotherapy followed by cART interruption during HIV-1 infection induces plasma protein markers of cellular immunity and neutrophil recruitment. van den Ham HJ; Cooper JD; Tomasik J; Bahn S; Aerts JL; Osterhaus ADME; Gruters RA; Andeweg AC; PLoS One; 2018; 13(2):e0192278. PubMed ID: 29389978 [TBL] [Abstract][Full Text] [Related]
13. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217 [TBL] [Abstract][Full Text] [Related]
14. Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/microl? Impact on immunovirological parameters. Pellegrin I; Thiébaut R; Blanco P; Viallard JF; Schrive MH; Merel P; Chêne G; Fleury H; Moreau JF; Pellegrin JL J Med Virol; 2005 Oct; 77(2):164-72. PubMed ID: 16121362 [TBL] [Abstract][Full Text] [Related]
15. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study. García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779 [TBL] [Abstract][Full Text] [Related]
16. A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial. Fox Z; Dragsted UB; Gerstoft J; Phillips AN; Kjaer J; Mathiesen L; Youle M; Katlama C; Hill A; Bruun JN; Clumeck N; Dellamonica P; Lundgren JD; Antivir Ther; 2006; 11(6):761-70. PubMed ID: 17310820 [TBL] [Abstract][Full Text] [Related]
17. Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial. Byakwaga H; Kelly M; Purcell DF; French MA; Amin J; Lewin SR; Haskelberg H; Kelleher AD; Garsia R; Boyd MA; Cooper DA; Emery S; J Infect Dis; 2011 Nov; 204(10):1532-40. PubMed ID: 21930607 [TBL] [Abstract][Full Text] [Related]
18. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group. Phillips AN; Eron J; Bartlett J; Kuritzkes DR; Johnson VA; Gilbert C; Johnson J; Keller A; Hill AM AIDS; 1997 Feb; 11(2):169-75. PubMed ID: 9030363 [TBL] [Abstract][Full Text] [Related]
19. The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study. De Luca A; de Gaetano Donati K; Colafigli M; Cozzi-Lepri A; De Curtis A; Gori A; Sighinolfi L; Giacometti A; Capobianchi MR; D'Avino A; Iacoviello L; Cauda R; D'Arminio Monforte A BMC Infect Dis; 2013 Sep; 13():414. PubMed ID: 24004495 [TBL] [Abstract][Full Text] [Related]